Interferon-&ggr;–Mediated Allograft Rejection Exacerbates Cardiovascular Disease of Hyperlipidemic Murine Transplant Recipients
Zhou J, Qin L, Yi T, Ali R, Li Q, Jiao Y, Li G, Tobiasova Z, Huang Y, Zhang J, Yun JJ, Sadeghi MM, Giordano FJ, Pober JS, Tellides G. Interferon-&ggr;–Mediated Allograft Rejection Exacerbates Cardiovascular Disease of Hyperlipidemic Murine Transplant Recipients. Circulation Research 2015, 117: 943-955. PMID: 26399469, PMCID: PMC4636943, DOI: 10.1161/circresaha.115.306932.Peer-Reviewed Original ResearchMeSH KeywordsAllograftsAnimalsAortic DiseasesApolipoproteins EAtherosclerosisCardiomyopathiesCardiovascular DiseasesDisease Models, AnimalFemaleGraft RejectionHeart TransplantationHemodynamicsHistocompatibility Antigens Class IIHyperlipidemiasInflammation MediatorsInterferon-gammaLymphocyte ActivationMaleMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutSignal TransductionTh1 CellsVentricular Dysfunction, LeftVentricular Function, LeftConceptsOrgan transplant recipientsCardiovascular diseaseTransplant recipientsEarly-onset cardiovascular diseaseEnd-stage organ failureNative coronary arteriesTh1-type cytokinesT helper cellsHost diseaseAlloimmune responseGraft rejectionAortic stiffeningOrgan failureVentricular dilatationAllogeneic graftsCardiovascular dysfunctionCoronary arteryAortic complianceRisk factorsEffective therapyCardiac contractilityMurine modelAnimal modelsSerological neutralizationImmune systemMHC class II-disparate heart but not skin allografts accelerate recipient cardiovascular disease (TRAN1P.934)
Zhou J, yi T, Qin L, Ali R, Li Q, Jiao Y, Li G, Zhang J, Sadeghi M, Pober J, Tellides G. MHC class II-disparate heart but not skin allografts accelerate recipient cardiovascular disease (TRAN1P.934). The Journal Of Immunology 2015, 194: 140.16-140.16. DOI: 10.4049/jimmunol.194.supp.140.16.Peer-Reviewed Original ResearchSkin allograftsCardiovascular diseaseAllograft rejectionCardiac allograftsHeart allograftsDonor miceSkin graftsMHC classAtherosclerotic lesionsApoE-/- mouse modelEarly activation marker CD69End-stage organ failureCD4 T cellsWeeks post transplantationActivation marker CD69Larger atherosclerotic lesionsHeart isograftsCardiac isograftsOrgan failurePost transplantationIL-12ACardiac functionElevated mRNA levelsEffective therapyOrgan transplantation